US$ 22.87
nct02637284 bpc-157 trial A human was registered. The results were submitted. Then they disappeared from public view. In 2015, a Phase I, randomized, placebo-controlled clinical trial (NCT02637284) was launched Stable Gastric Pentadecapeptide BPC 157
Description
Medical Science Monitor Though clinical trials for humans remain limited, animal models and anecdotal evidence strongly suggest the potential of these peptides

Ipamorelin, with its shorter half-life and cleaner cortisol/prolactin profile, is added to provide pulsatile GHRP-driven GH release layered on MK-677's sustained baseline
doi:10.1038/s41374-018-0025-8 60

doi: 10.1016/j.bbrc.2006.05.042 37 YoungGSCholerisELundFEKirklandJB
